StoneX Group’s DataMeds AI MEDS Stock Holding History

StoneX Group’s Portfolio MEDS Stock Details MEDS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-433	Closed	-$8.65K	–	1286
2025 Q4	$8.65K	Buy	+433	New	+$12.7K	﹤0.01%	1011

Other funds holding MEDS

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

ACT Advisors Asheville, North Carolina $301M AUM 23.36% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

StoneX Group's MEDS Position: Q1 2026 in Review

StoneX Group sold out of DataMeds AI (MEDS) in Q1 2026, closing a stake of 433 shares — an estimated $8.65K sold.

StoneX Group first reported a position in MEDS in Q4 2025 and held it in 1 quarter. The position peaked at $8.65K in Q4 2025. 13 funds tracked by Wall St. Rank hold MEDS as of Q1 2026.

StoneX Group reported no remaining DataMeds AI position as of Q1 2026 after selling out during the quarter.
StoneX Group sold 433 DataMeds AI shares in Q1 2026, an estimated $8.65K.
StoneX Group first reported a position in DataMeds AI in Q4 2025 and held it in 1 quarter.
StoneX Group's DataMeds AI position peaked at $8.65K in Q4 2025.
13 funds tracked by Wall St. Rank held DataMeds AI as of Q1 2026.

Based on StoneX Group's 13F filing for Q1 2026, filed 14 May 2026.